RT Journal Article SR Electronic T1 A case-control, multicentre study of consecutive patients with COVID-19 and acute (myo)pericarditis: incidence, risk factors, clinical characteristics and outcomes JF Emergency Medicine Journal JO Emerg Med J FD BMJ Publishing Group Ltd and the British Association for Accident & Emergency Medicine SP 402 OP 410 DO 10.1136/emermed-2020-210977 VO 39 IS 5 A1 Òscar Mirò A1 Manel Sabaté A1 Sònia Jiménez A1 Alexandre Mebazaa A1 Gemma Martínez-Nadal A1 Pascual Piñera A1 Guillermo Burillo-Putze A1 Alfonso Martín A1 Francisco Javier Martín-Sánchez A1 Javier Jacob A1 Aitor Alquézar-Arbé A1 Eric Jorge García-Lamberechts A1 Pere Llorens A1 Juan González del Castillo A1 , YR 2022 UL http://emj.bmj.com/content/39/5/402.abstract AB Objective To estimate incidence, risk factors, clinical characteristics and outcomes of acute (myo)pericarditis (AMP) in patients with COVID-19.Methods Case-control, retrospective review, consecutive case inclusion performed in 62 Spanish EDs. All COVID-19 patients with AMP (cases) were compared in clinical characteristics and outcomes with COVID-19 without AMP (control group A) and non-COVID patients with AMP (control group B). We estimated unadjusted standardised incidence (SI, not adjusted by population’s age/sex) of AMP in COVID-19 and non-COVID populations (per 100 000/year).Results We identified 67 AMP in COVID-19 patients (SI=56.5, OR with respect to non-COVID patients=4.43, 95% CI=3.98 to 4.94). Remarkably, COVID-19 cases presented with chest pain less frequently than non-COVID patients and had less typical ECG changes, higher NT-proBNP (N-terminal prohormone of brain natriuretic peptide), more left and right ventricular dysfunction in echocardiography and more need of inotropic/vasopressor drugs. Admission to intensive care was higher than control group A (OR=3.22, 95% CI=1.43 to 7.23), and in-hospital mortality was higher than control group B (OR=7.75, 95% CI=2.77 to 21.7).Conclusion AMP is unusual as a form of COVID-19 presentation (about 1‰ cases), but SI is more than fourfold higher than non-COVID population, and it is less symptomatic, more severe and has higher in-hospital mortality; therefore, rapid recognition, echocardiographic assessment of myopericardial inflammation/dysfunction and treatment with vasoactive drugs when needed are recommended in AMP in patients with COVID-19.All data relevant to the study are included in the article or uploaded as supplementary information. Data are available from the authors with the permission of respectively intitutions. The data that support the findings of this study are available from the corresponding author, (ÒM), on reasonable request.